Supernus links depression drug to fast responses in phase 2 trial

Supernus Pharmaceuticals has linked its mTORC1 activator to rapid improvements in adults with major depressive disorder (MDD) in a small trial, pointing to one possible path forward for a candidate that is barreling toward phase 2b data in another indication.